Regulus Therapeutics reported $4.7M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Alnylam Pharmaceuticals ALNY:US $ 605.96M 89.75M
AstraZeneca AZN:LN 22740M 146M
Astrazeneca AZN:US $ 22740M 146M
Biogen BIIB:US $ 3946.6M 351.6M
Celldex Therapeutics CLDX:US $ 14.56M 1.97M
Gilead Sciences GILD:US $ 8558M 3052M
GlaxoSmithKline GSK:LN 24278M 608M
Intercept Pharmaceuticals ICPT:US $ 151.04M 15.78M
Intrexon XON:US $ 25.6M 9.04M
Lexicon Pharmaceuticals LXRX:US $ 18.9M 3.22M
Ligand Pharmaceuticals LGND:US $ 42.58M 0.91M
Merk MRK:US $ 22316M 1556M
Omeros OMER:US $ 35.07M 16.72M
Regulus Therapeutics RGLS:US $ 4.7M 0.53M
Sangamo Biosciences SGMO:US $ 118.53M 9.36M
Spectrum Pharmaceuticals SPPI:US $ 39.21M 14.02M
Takeda 4502:JP Y 2145730M 336476M
Vital Therapies VTL:US $ 11.46M 0.06M
YTE INCY:US $ 886.16M 31.86M